Features, Evaluation, and Treatment of Coronavirus (COVID-19)
- PMID: 32150360
- Bookshelf ID: NBK554776
Features, Evaluation, and Treatment of Coronavirus (COVID-19)
Excerpt
Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has had a catastrophic effect on the world, resulting in more than 6 million deaths worldwide. After the first cases of this predominantly respiratory viral illness were reported in Wuhan, Hubei Province, China, in late December 2019, SARS-CoV-2 rapidly disseminated worldwide. This compelled the World Health Organization (WHO) to declare it a global pandemic on March 11, 2020.
Even though substantial progress in clinical research has led to a better understanding of SARS-CoV-2, many countries continue to have outbreaks of this viral illness. These outbreaks are primarily attributed to the emergence of mutant variants of the virus. Like other RNA viruses, SARS-CoV-2 adapts with genetic evolution and developing mutations. This results in mutant variants that may have different characteristics than their ancestral strains. Several variants of SARS-CoV-2 have been described during the course of this pandemic, among which only a few are considered variants of concern (VOCs). Based on the epidemiological update by the WHO, 5 SARS-CoV-2 VOCs have been identified since the beginning of the pandemic:
Alpha (B.1.1.7): First variant of concern, which was described in the United Kingdom (UK) in late December 2020
Beta (B.1.351): First reported in South Africa in December 2020
Gamma (P.1): First reported in Brazil in early January 2021
Delta (B.1.617.2): First reported in India in December 2020
Omicron (B.1.1.529): First reported in South Africa in November 2021
Despite the unprecedented speed of vaccine development against the prevention of COVID-19 and robust global mass vaccination efforts, the emergence of new SARS-CoV-2 variants threatens to overturn the progress made in limiting the spread of this disease. This review aims to comprehensively describe the etiology, epidemiology, pathophysiology, and clinical features of COVID-19. This review also provides an overview of the different variants of SARS-CoV-2 and the guideline-recommended treatment (as of January 2023) for managing this disease.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
Similar articles
-
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19).2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 34033342 Free Books & Documents.
-
Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived).2023 Jan 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jan 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 34662052 Free Books & Documents.
-
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.Front Med (Lausanne). 2022 May 20;9:849217. doi: 10.3389/fmed.2022.849217. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35669924 Free PMC article. Review.
-
Molecular evolution of SARS-CoV-2 from December 2019 to August 2022.J Med Virol. 2023 Jan;95(1):e28366. doi: 10.1002/jmv.28366. J Med Virol. 2023. PMID: 36458547 Free PMC article. Review.
-
Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).Viruses. 2023 Sep 15;15(9):1933. doi: 10.3390/v15091933. Viruses. 2023. PMID: 37766339 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous